Kodiak Sciences’ (KOD) Neutral Rating Reaffirmed at Chardan Capital

Kodiak Sciences (NASDAQ:KOD)‘s stock had its “neutral” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital’s target price indicates a potential downside of 9.43% from the company’s current price.

KOD has been the topic of a number of other reports. JPMorgan Chase & Co. upgraded Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 target price on the stock in a research report on Thursday, August 14th. Wall Street Zen upgraded Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Friday, September 26th. Barclays raised shares of Kodiak Sciences from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $7.00 to $17.00 in a research note on Thursday, September 25th. HC Wainwright upped their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a report on Monday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kodiak Sciences has an average rating of “Hold” and a consensus price target of $13.20.

Kodiak Sciences Stock Performance

NASDAQ KOD traded up $0.40 during trading on Monday, hitting $15.46. The stock had a trading volume of 49,194 shares, compared to its average volume of 514,194. The stock has a market capitalization of $816.49 million, a price-to-earnings ratio of -4.06 and a beta of 2.67. Kodiak Sciences has a one year low of $1.92 and a one year high of $19.39. The stock has a 50 day simple moving average of $10.24 and a 200 day simple moving average of $6.04.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). On average, sell-side analysts predict that Kodiak Sciences will post -3.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KOD. US Bancorp DE grew its position in Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after buying an additional 5,276 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in Kodiak Sciences in the 1st quarter valued at $28,000. Headlands Technologies LLC grew its stake in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after buying an additional 5,815 shares during the last quarter. Walleye Capital LLC acquired a new position in Kodiak Sciences during the 1st quarter valued at $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Kodiak Sciences by 21.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company’s stock worth $56,000 after acquiring an additional 2,691 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.